Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27143717 | 1.00 | CYP17A1 (0.38) | CYP17A1SCN9ARXRAGRIN1GRIN2B | |
| SCHEMBL27132783 | 0.87 | RXRA (0.36) | SCN9ARXRAGRIN1GRIN2BCHRM4 | |
| SCHEMBL30848042 | 0.87 | RXRA (0.36) | SCN9ARXRAGRIN1GRIN2BCHRM4 | |
| SCHEMBL30848075 | 0.86 | CYP2C9 (0.33) | SCN9ASCN2ASCN5A | |
| SCHEMBL27138147 | 0.86 | CYP2C9 (0.33) | SCN9ASCN2ASCN5A | |
| SCHEMBL30848066 | 0.86 | RXRA (0.34) | SCN9ARXRAGRIN1GRIN2BCHRM4 | |
| SCHEMBL27132716 | 0.86 | RXRA (0.34) | SCN9ARXRAGRIN1GRIN2BCHRM4 | |
| SCHEMBL30847891 | 0.86 | CYP17A1 (0.38) | CYP17A1SCN9ASCN2ASCN5A | |
| SCHEMBL27143429 | 0.86 | CYP17A1 (0.38) | CYP17A1SCN9ASCN2ASCN5A | |
| SCHEMBL30848041 | 0.85 | RXRA (0.38) | SCN9ARXRAGRIN1GRIN2BCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577536-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | Hotspot Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |